Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)

  • Authors:
    • Alexandra Dana Pușcaș
    • Andreea Cătană
    • Cristian Pușcaș
    • Iulia Ioana Roman
    • Corina Vornicescu
    • Mihaela Șomlea
    • Remus Ioan Orăsan
  • View Affiliations

  • Published online on: May 28, 2019     https://doi.org/10.3892/etm.2019.7624
  • Pages: 875-880
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Psoriasis is a chronic, inflammatory disease with a complex pathogenesis that is not yet fully understood. Although it is a multifactorial disease, the genetic factor has a major role in the pathogenesis of psoriasis. Genome wide association studies have identified over 50 genetic loci associated with psoriasis risk. Beside TNF-α or IL-23, the IL-17 family is a newer group that has proven implications in the pathogenesis of psoriasis. The most important members of the family, with pro-inflammatory qualities, are IL-17A and IL-17F. These interleukins are produced by a varied number of cells, but by far the most important are Th17 cells. Of the patients 20-30% present moderate-to-severe psoriasis, therefore, systemic medication (phototherapy, methotrexate, cyclosporine, acitretin or biologic agents) is mandatory. The necessity of an individualized treatment plan, for each patient, is imperative in order to establish the best strategy for non-responders to classical treatment or to other biologic treatments. The discovery of Th17 pathway improved the treatment and prognosis of psoriasis. Anti-psoriatic agents against IL-17 or its receptors are a novel group of biologic agents; these include ixekizumab, secukinumab and brodalumab. Polymorphisms of IL-17 family have been correlated with the severity and response to treatment in psoriasis, and also with the risk of inflammatory, infectious, autoimmune or neoplastic pathologies. The significant difference in the presence or absence of susceptibility loci in different population is due to genetic background and environmental factors that have a major impact on disease predisposition. In this study, we reviewed the importance and influence of the IL-17 polymorphisms as predictors of response to treatment and severity of the disease.
View Figures
View References

Related Articles

Journal Cover

August-2019
Volume 18 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pușcaș AD, Cătană A, Pușcaș C, Roman II, Vornicescu C, Șomlea M and Orăsan RI: Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review). Exp Ther Med 18: 875-880, 2019
APA
Pușcaș, A.D., Cătană, A., Pușcaș, C., Roman, I.I., Vornicescu, C., Șomlea, M., & Orăsan, R.I. (2019). Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review). Experimental and Therapeutic Medicine, 18, 875-880. https://doi.org/10.3892/etm.2019.7624
MLA
Pușcaș, A. D., Cătană, A., Pușcaș, C., Roman, I. I., Vornicescu, C., Șomlea, M., Orăsan, R. I."Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)". Experimental and Therapeutic Medicine 18.2 (2019): 875-880.
Chicago
Pușcaș, A. D., Cătană, A., Pușcaș, C., Roman, I. I., Vornicescu, C., Șomlea, M., Orăsan, R. I."Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment (Review)". Experimental and Therapeutic Medicine 18, no. 2 (2019): 875-880. https://doi.org/10.3892/etm.2019.7624